Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cardiff Oncology (CRDF) EBITDA Margin (2016 - 2025)

Cardiff Oncology (CRDF) has disclosed EBITDA Margin for 15 consecutive years, with 3220.99% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin rose 510484.0% to 3220.99% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 8256.32% through Dec 2025, down 114360.0% year-over-year, with the annual reading at 8256.32% for FY2025, 113319.0% down from the prior year.
  • EBITDA Margin hit 3220.99% in Q4 2025 for Cardiff Oncology, up from 9978.33% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 3220.99% in Q4 2025 to a low of 14964.86% in Q1 2022.
  • Historically, EBITDA Margin has averaged 9207.82% across 5 years, with a median of 8231.52% in 2021.
  • Biggest five-year swings in EBITDA Margin: surged 918731bps in 2024 and later plummeted -786132bps in 2025.
  • Year by year, EBITDA Margin stood at 7162.41% in 2021, then dropped by -2bps to 7337.5% in 2022, then rose by 10bps to 6623.08% in 2023, then dropped by -26bps to 8325.83% in 2024, then soared by 61bps to 3220.99% in 2025.
  • Business Quant data shows EBITDA Margin for CRDF at 3220.99% in Q4 2025, 9978.33% in Q3 2025, and 12212.4% in Q2 2025.